Coherus BioSciences (NASDAQ:CHRS) announced on Thursday that it would receive $40M in cash upfront as part of an agreement to divest its biosimilar therapy Yusimry targeted at AbbVie’s (ABBV) ...
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend ...
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic ...
(RTTNews) - Coherus BioSciences, Inc. (CHRS) announced Thursday divested YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. or HKF for up-front all-cash consideration of $40 ...
Meitheal, a biopharmaceutical company focused on developing and commercializing generic injectables, fertility, biologic and branded products, has gained exclusive U.S. commercial rights to Yusimry, a ...
The Verizon checkmark is gone as the company recasts itself as a ‘one-stop-shop’ for internet and entertainment. The Verizon checkmark is gone as the company recasts itself as a ‘one-stop-shop’ for ...
The Ducks today unveiled the club’s new logo, home and away jerseys as part of a brand evolution. “As our organization enters a new chapter of Anaheim Ducks hockey, we are proud to reveal our new, ...
FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.
The internet is good for plenty of things, but perhaps its most underrated value is its ability to turn an absolute nothingburger of a question into a worldwide search for truth. Case in point: the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback